Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1589-1593

  Li, Hong ^a   Hu, Yaohong ^a   Li, Na ^a   Zhou, Yan ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver fibrosis; Survival; Transcatheter arterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN TYPE 3; COLLAGEN TYPE 4; EPIRUBICIN; FLUOROURACIL; HYALURONIC ACID; IODINATED POPPYSEED OIL; LAMININ; MITOMYCIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMOEMBOLIZATION; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; COLLAGEN TYPE III; COLLAGEN TYPE IV; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; HYALURONIC ACID; IODIZED OIL; KAPLAN-MEIER ESTIMATE; LAMININ; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MITOMYCIN; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84873032643     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1589     Document Type: Article

References (20)

1. Bruix J (1997). Treatment of hepatocellular carcinoma. Hepatology, 25, 259-62.
2. Camma C, Schepis F, Orlando A, et al (2008). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 224, 47-54.
3. Chen MS, Li JQ, Zhang YQ, et al (2002). High does iozedized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol, 8, 74.
4. Chen Y, Feng Y, Dai L, et al (2003). Screening and evaluation of non-traumatic diagnostic indexes to compensatory hepatic cirrhosis. Chinese Hapar Disease J, 11, 220-5.
5. Chung JW, Park JH, Han JK, et al (2007). Hepatic tumors: predisposing fators for complications of transeatheter oily chemoembolization. Radiology, 198, 33-40.
6. Chung JW, Park JH, Han JK, et al (1996). Hepatic tumors: predispo sing factors for complications of transcatheter oily chemoembolization. Radiology, 198, 33-40.
7. Feng G, Wu H, Xu L, et al (2002). The related to the fibrotic indicators of primary hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Chinese J of Hepatobiliary Surg, 8, 414-6.
8. Hu D, Li Z, Wang N, et al (2002). TACE treatment of Hepatic Carcinoma: A Comparative study of low dose versus conventional dose. Clin Radiol J, 23, 502-6.
9. Ikeda K, Kumada H, Saitoh S, et al (2001). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the cox proportional hazard model. Cancer, 68, 2150-4.
10. Kamada K, Nakanishi T, Kitamoto M, et al (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol, 12, 847-54.
11. Kamada K, Nakanishi T, Kitamato M, et al (2009). Long-term prognosis of patients undergoing transcatheter arterial chenmoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin liopiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Interv Radiol, 12, 843-7.
12. Li H, Hu D, Zhao Y, et al (2000). The relationship between curative effect of hepatic arterial chemoembolization and dose of Iodized Oil. China Hepatol J, 12, 235-6.
13. Lu W, Li Y, He X, et al (2004). A comparative study on the changes of serum fibrosis indicators after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. J Interv Radiol, 13, 247-9.
14. Lu W, Lu S (2006). Progress in diagnosis and treatment of liver fibrosis. Int J Digest Dis, 26, 13-6.
15. Lu W, Li Y (2002). Hepatic carcinoma treated with trancatheter arterial chemoembolization. Clin Radiol J, 21, 735.
16. Lu W, Li Y, Li Z, et al (2003). A comparative study on necrosis and apoptosis of hepatocellular carcinoma cells after TACE with use of low-dose and conventional-dose anticancer drugs. Chinese J Radiol, 37, 232-7.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guide lines to evaluate the response to treatment in solidtumors. JNCI, 92, 205-16.
18. Xiao C, Zheng L, Jiang X, et al (1997). Observation of liver damage caused by hepatic arterial chemoembolization. China Radiol J, 31, 777-9.
19. Yan L (2002). Liver Surgery. Peking: The People's Medical Publishing House, 263-509.
20. Zhu S, Shan H, Huang M, et al (2000). The content changes of serum liver fibrosis indicators after transarterial chemoembolization for primary hepatic carcinoma and their clinical significance. J Clin Radiol, 19, 208-9.